Glucagon-like-peptide 1 (GLP-1) is a gut hormone that has a good chance to make its way from the basic science experiment to the field of clinical usage as a treatment of type II diabetes mellitus. However, more research needs to be done before GLP-1 or a synthetic analogue is ready for clinical application. The first International Symposium on GLP-1 in 1993 brought together the leading experts in the field who discussed a wide range of topics from basic research to human studies. This symposium report reflects the state of the art, providing an overview of GLP-1's biological actions and its possible therapeutic applications in the treatment of non-insulin-dependent diabetics.
